RGC (Regencell) Net earnings per share (EPS TTM)
The fragility of Regencell Bioscience (RGC) defensive barriers due to prolonged phytopharmaceutical testing is offset when the 12-month net income per share chart on GURU.Markets includes the fresh parameter -0.02. This resilience is further confirmed by strict government oversight and high entry barriers in neuropharmaceuticals, as well as the synergy of a tight-knit circle of neurology experts united by a unique scientific mission and targeted funding.
Regencell Bioscience Ltd - analytical breakdowns and key metrics (RGC)
- current quotes and average value forecast:
- business market valuation indicators:
- business book valuation details:
- debt and liquidity data:
Debt to Equity Regencell Bioscience|RGC - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Regencell|RGC - Aggregate Debt Obligations|Debts to Book Capitalization Regencell Bioscience Holdings Limited|RGC - Company Long-Term Debt|Company Short-Term Debts Regencell Bioscience|Quick Liquidity regencellbioscience.com
- net income and valuation multiples indicators:
RGC - Company Net Income|Expected Profit Regencell Bioscience|RGC - Business Payback Period|Forward P/E Multiple Regencell Bioscience Holdings Limited|RGC - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Regencell Bioscience Holdings Limited|RGC - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Regencell Bioscience|RGC - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months regencellbioscience.com|RGC - Earnings per share growth this year|Earnings growth forecast for next year Regencell Bioscience
General company analysis:Regencell Bioscience (RGC)
Net income per share over 12 months determines the portion of total income attributable to a single security, allowing for an assessment of real capital generation efficiency without accounting for share dilution. By analyzing the net income per share over the last four quarters, an investor compares the financial return against the expenditures of Regencell Bioscience (RGC) on drug synthesis automation and costly clinical trials.
Competitor analysis for Regencell Bioscience
BIIB - Earnings per share for the last twelve months|NBIX (neurocrine.com) - Earnings per share for the last 12 months|AXSM: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months ACADIA Pharma|XENE (Xenon Pharmaceuticals Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Viking Therapeutics Corp VKTX|Earnings per share for the last twelve months Supernus Pharmaceuticals (SUPN)|Earnings per share for the last twelve months CPRX (catalystpharma.com)|Earnings per share for the last twelve months Denali Therapeutics Inc. DNLI|Harmony Biosciences Inc - Earnings per share for the last twelve months|BHVN: Net earnings per share for the last 12 months|Earnings per share for the trailing year AMLX (Amylyx Corp)|TRVI: Net earnings per share (EPS TTM)|PRAX (praxismedicines.com) - Earnings per share for the last twelve months|AVXL (Anavex Life Sciences Corp.) - Net earnings per share (EPS TTM)|CeriBell Inc (CBLL) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Prothena Corp (PRTA)|ALEC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Annexon, Inc. ANNX|Net earnings per share for the last four quarters Omeros Corp (OMER)|Neurogene - Net earnings per share (EPS TTM)|AC Immune S.A. (ACIU) - Net earnings per share for the last 12 months|VYGR: Net earnings per share (EPS TTM)|NMRA - Net earnings per share for the last four quarters|SCLX (Scilex Holding Company) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months tevogen.com TVGN|Earnings per share for the last twelve months Alpha Cognition (ACOG)|Cognition Therapeutics Inc. - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) IKT (Inhibikase)|SAVA - Net earnings per share for the last 12 months|Assertio Therapeutics - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Coya Therapeutics, Inc.|vistagen.com (VTGN) - Earnings per share for the last twelve months|Ovid Therapeutics - Earnings per share for the trailing year|ABOS (Acumen Pharma) - Net earnings per share (EPS TTM)|CRVO - Net earnings per share for the trailing year|Net earnings per share (EPS TTM) ATHE|Net earnings per share for the last 12 months clene.com CLNN|Earnings per share for the last twelve months PepGen PEPG|JUNS: Earnings per share for the last 12 months|Relmada - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Annovis Bio Corporation|GRCE (gracetx.com) - Net earnings per share for the last 12 months|fireflyneuro.com (AIFF) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months ANEW Medical|NRSN: Earnings per share for the trailing year|Earnings per share for the last twelve months Reviva Pharmaceuticals Holdings (RVPH)|MTVA - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months NeurAxis, Inc. NRXS|Earnings per share for the trailing year HSDT|Passage Bio Corp - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Neuphoria Therapeutics Inc.|NERV: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Athira Pharma Corp ATHA|ADXN (Addex Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Alzamend ALZN|Earnings per share for the last twelve months Cyclerion Therapeutics (CYCN)|protagenic.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) KTTA (Pasithea Therapeutics Corp.)|CRGT - Net earnings per share for the last 12 months|Avenue Therapeutics - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months brainstorm-cell.com|Cara Therapeutics (CARA) - Earnings per share for the last twelve months|CHRO (Chromocell Therapeutics Corp) - Earnings per share for the last twelve months|Earnings per share for the last twelve months Eliem Therapeutics, Inc.|Earnings per share for the last twelve months ITCI|Net earnings per share for the last 12 months LBPH (Longboard Pharmaceuticals)|MRNS (marinuspharma.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) NKGN (NKGen Biotech)|NeuroBo Pharmaceuticals Inc - Earnings per share for the last twelve months|Sage Therapeutics, Inc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Synaptogenix, Inc SNPX|Trevena, Inc. (TRVN) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Vigil Neuroscience, Inc. (VIGL)|Earnings per share for the last twelve months Anew Medical|Cerevel Therapeutics Inc (CERE) - Net earnings per share for the last four quarters
